Private · Company · Aksjeselskap
SERCA PHARMACEUTICALS AS
921 663 846 ↗Research and experimental development on natural sciences and engineering · NACE 72.100Oslo
↳ Brreg · companies
Group financialsNOK
FY21 · 2057kFY22 · 1985kFY23 · 3572kFY24 · 4715kFY25 · 2963k
RevenueNet profit
Regnskapsregisteret · company_revenue
Job ads on NAV Arbeidsplassen12 MO
No job ads on record in the last 12 months.
NAV Arbeidsplassen · company_job_ad_months
Public contracts · won → est. expiryaward dates from Doffin/TED · hatched = our estimate, end dates aren't published
0 wins
Doffin/TED · company_tender_wins
Key figuresBrønnøysund
FY21FY22FY23FY24FY25TREND
Revenue2057k1985k3572k4715k2963k
Operating result-2663k-2749k-4421k-1527k11k
Net result-2654k-2796k-4424k-1159k132k
Regnskapsregisteret · company_revenue
MoneyNOK
Revenue
kr 2.96M
Operating result
kr 11k
Net result
kr 132k
Total assets
kr 40.2M
Equity
kr 27.9M
FY2025 kr 2.96M vs FY2024 kr 4.71M · -37% revenue
Regnskapsregisteret · company_financials · FY2025 (company)
Activitylast 24 mo
No job-ad activity on file
totals on file · ads-over-time series not yet in Intelligo
Registry changes
Field change · kapital{"antallAksjer": 895550, "belop": 895550.0, "innfortDato": "2024-01-08", "type": "Aksjekapital", "valuta": "NOK"} → {"antallAksjer": 1046131, "belop": 1046131.0, "innfortDato": "2026-07-21", "type": "Aksjekapital", "valuta": "NOK"}2026-07-23
Field change · vedtektsdato2023-11-27 → 2026-02-252026-07-23
Accounts filed · sisteInnsendteAarsregnskap2024 → 20252026-06-19
NAV + JobStream · company_hiring · Brreg · company_changes
From the FY2025 accounts
FILEDAccounts filed for FY2025.
AUDITAudited by UNIC REVISJON AS.
BALANCEEquity kr 27.9M.
Regnskapsregisteret + Brreg roles · the annual-report PDF is a paid Brønnøysund document, so these are the filed facts, not extracted prose
Timelineall sources
field_change: kapital{"antallAksjer": 895550, "belop": 895550.0, "innfortDato": "2024-01-08", "type": "Aksjekapital", "valuta": "NOK"} -> {"antallAksjer": 104...Registry · 2026-07-23
field_change: vedtektsdato2023-11-27 -> 2026-02-25Registry · 2026-07-23
accounts_filed: sisteInnsendteAarsregnskap2024 -> 2025Registry · 2026-06-19
Revisors konklusjonThe auditor concludes that the financial statements comply with statutory requirements and give a true and fair view. — oppfyller arsregn...Annual report · 2025-12-31
Presisering om vesentlig usikkerhet fortsatt driftThe audit report contains a material uncertainty related to going concern paragraph referring to note 10. — erbeskreveti10,at detforeligg...Annual report · 2025-12-31
Note 10 – usikkerhet fortsatt driftThe company itself states there is uncertainty about going concern, being in a development phase with limited operating revenue and depen...Annual report · 2025-12-31
Avhengig av ekstern finansieringOperations depend on external financing because the company is in a development phase with limited revenues. — Selskapet er i en utviklin...Annual report · 2025-12-31
Fortsatt drift lagt til grunnThe accounts are nevertheless prepared on a going concern basis. — Arsregnskapeteravlagtunderforutsetningomfortsattdrift.Annual report · 2025-12-31
Kapitalforhøyelse etter balansedagenA capital increase with total contributions of NOK 16.9 million was resolved in a board meeting on 18 February 2026, after the balance sh...Annual report · 2025-12-31
Offentlig tilskudd utløst av kapitalutvidelsenThe capital increase triggers a public grant of NOK 16 million, securing full financing of phase 1. — offentlig tilskudd pa NoK 16 millio...Annual report · 2025-12-31
Aksjekapital og egenkapitalShare capital is NOK 895 550 with share premium NOK 19 924 852 and total equity NOK 27 895 940 at 31.12.2025. — Egenkapital 31.12.2025 8...Annual report · 2025-12-31
EierstrukturSarsia Seed Fond II AS holds 40.45 % and Inven2 AS 26.13 % of the shares. — INVEN2 AS SARSIASEEDFONDIIAS 362 247 234 032 26,13 Ordina...Annual report · 2025-12-31
Ytelser til ledende personerNo salary or other remuneration was paid to senior personnel. — Det erikkegittlonn,annen godtgjorelsemv.til ledendepersoner.Annual report · 2025-12-31
Lån og sikkerhetsstillelseNo loans or security have been granted to members of the governing bodies. — Det erikkegitt lanellersikkerhetsstillelsetil medlemmer avst...Annual report · 2025-12-31
Aktiverte utviklingskostnaderDevelopment costs for a new drug for treatment of heart infarction are capitalised and will be amortised from completion. — Selskapet har...Annual report · 2025-12-31
Ingen nedskrivningThe board finds no indication of impairment, so the capitalised development costs were not written down at 31.12.2025. — nedskrivning avd...Annual report · 2025-12-31
Antall årsverkThe company reports zero man-years in the financial year. — Antall arsverk i regnskapsaretAnnual report · 2025-12-31
Driftsinntekt fra ForskningsrådetAll 2025 operating income is IPN support of NOK 2 962 524 recognised from the Research Council of Norway. — For prosjektaret 2025 er det ...Annual report · 2025-12-31
SkatteFUNN-prosjektThe company has an industrial research project approved under the SkatteFUNN scheme. — Forskningsrad et industrielt forskningsprosjektiSk...Annual report · 2025-12-31
Revisor og signeringThe audit report is signed in Oslo on 12 May 2026 by state authorised auditor Knut Henrik Hammer-Holt of Unic Revisjon AS. — UnicRevisjon...Annual report · 2025-12-31
Auditor's clean opinionPwC concludes that the financial statements comply with law and give a true and fair view of the company's position at 31 December 2023. ...Annual report · 2023-12-31
Auditor identityThe audit report is signed by Hans-Christian Berger, state authorised auditor, of PricewaterhouseCoopers AS. — Hans-Christian Berger Sta...Annual report · 2023-12-31
Going concern uncertainty (note 8)Note 8 states that there is uncertainty related to going concern. — Deterknyttetusikkerhettilfortsattdrift.Annual report · 2023-12-31
Going concern - form answerThe Brreg form answer confirms uncertainty about going concern is present (Ja). — Er det usikkerhet om fortsatt drift?:JaAnnual report · 2023-12-31
Dependence on new financingThe company depends on additional liquidity, and management, board and main owners will work to secure further financing for 2024-2025. —...Annual report · 2023-12-31
No remuneration to managementNo salary or other remuneration was paid to leading personnel. — Deterikkegittlonn,annengodtgjorelsemv.tilledendepersoner.Annual report · 2023-12-31
CEO consultancy fees (related party)The CEO delivers consulting services to the company and invoiced NOK 451 650 excl. VAT for work performed in 2023. — Selskapets daglig le...Annual report · 2023-12-31
OwnershipSarsia Seed Fond II AS is the largest shareholder with 309 615 shares, 43.15%. — SARSIASEEDFONDIIAS Aksjonaerer Antall aksjer 309615 ...Annual report · 2023-12-31
Share capitalTotal number of shares is 717 496, representing 100% of capital. — Totalt antall aksjer 717496 100Annual report · 2023-12-31
Equity injection registered lateShare premium was injected in 2023 but only registered/journalised in 2024. — Detblei2023skutt innoverkursiselskapet,somblejournalforti2024.Annual report · 2023-12-31
Skiwo · company_events
Tenders0 wins · 0 losses
No recorded tender wins.
Relevant open tenders — matched NACE 72.100 ↔ CPV
subscribers sharpen matches with per-company keywords
open-tender matching (NACE ↔ CPV) awaits Intelligo's open-tenders view
Doffin/TED · company_tender_wins · 2026-08-03
People4 roles
BOARD · 3 ROLES
registered roles only · website-employee lookup awaits the crawler
Roles from Brreg, shown for business contact only. No birth date is shown or exported (purpose limitation, GDPR Art. 6(1)(f)).
Brreg · company_people
Structure
Owned by ↑ · top 8
SARSIA SEED FOND II AS
40.4%INVEN2 AS
26.1%SATURN INVEST AS
10.9%MP PENSJON PK
9.1%HERSETH AS
4.5%K OG K AS
2.6%IFH CONSULTING AS
2.5%DRUG DISCOVERY LABORATORY AS
0.3%Aksjonærregisteret · company_ownership · 2025 · both directions
LocationOslo
Oslo
municipality only · street address + coordinates not yet in Intelligo
Brreg · registered municipality